Primary refractory disease in non-Hodgkin lymphoma (NHL)

被引：0

作者：

d'Amore, F. ^{[1
]}

Brown, P. ^{[2
]}

Pedersen, L. M. ^{[3
]}

Pulczynski, B. B. ^{[4
]}

Pedersen, M. ^{[5
]}

Gadeberg, O. ^{[6
]}

Bukh, A. ^{[7
]}

Hansen, M. ^{[8
]}

Pulczynski, S. ^{[9
]}

Ingeberg, S. ^{[10
]}

Andersen, T. M. ^{[11
]}

Frederiksen, M. ^{[12
]}

Moeller, M. B. ^{[3
]}

Mortensen, L. S. ^{[13
]}

机构：

[1] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark

[2] Herlev Univ Hosp, Copenhagen, Denmark

[3] Odense Univ Hosp, DK-5000 Odense, Denmark

[4] Viborg Hosp, Viborg, Denmark

[5] Roskilde Hosp, Roskilde, Denmark

[6] Viborg Hosp, Vejle, Denmark

[7] Aalborg Hosp, Aalborg, Denmark

[8] Rigshosp, DK-2100 Copenhagen, Denmark

[9] Holstebro Hosp, Holstebro, Denmark

[10] Naestved Hosp, Naestved, Denmark

[11] Esbjerg Cent Hosp, Esbjerg, Denmark

[12] Haderslev Hosp, Haderslev, Denmark

[13] UNI C, Aarhus, Denmark

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：132 / 132

页数：1

共 50 条

[1] Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
Davids, Matthew Steven
Roberts, Andrew Warwick
Seymour, John Francis
Wierda, William G.
Puvvada, Soham D.
Gressick, Lori A.
Alter, Debbie
Zhou, Lang
Kim, Su Young
Verdugo, Maria
Gerecitano, John F.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)
Davids, M. S.
Roberts, A. W.
Seymour, J. F.
Wierda, W. G.
Puvvada, S. D.
Gressick, L.
Alter, D.
Zhou, L.
Kim, S. Y.
Verdugo, M.
Gerecitano, J. F.
HAEMATOLOGICA, 2017, 102 : 218 - 219
[3] Venetoclax (VEN) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).
Davids, M.
Roberts, A.
Seymour, J.
Wierda, W.
Puvvada, S.
Gressick, L.
Alter, D.
Zhou, L.
Kim, S.
Verdugo, M.
Gerecitano, J.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 74 - 74
[4] Non-Hodgkin Lymphoma (NHL) in Pakistan
Pervez, Shahid
INTERNATIONAL JOURNAL OF MOLECULAR AND CELLULAR MEDICINE, 2012, 1 (01) : 62 - 63
[5] ASHAP salvage therapy for recurrent and refractory Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
Hanel, M
Hoffknecht, MM
Peters, SO
Fiedler, F
Hanel, A
Kruger, WH
Zeller, W
Braumann, D
Illiger, HJ
Metzner, B
Schubert, JC
Schmitz, N
Weh, HJ
Kroger, N
Zander, AR
BLOOD, 1997, 90 (10) : 4559 - 4559
[6] Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma (NHL)
Schmitt, M.
Sayer, H. G.
Hilgendorf, I
Treschl, A.
Junghanss, C.
Borchert, K.
Koenigsmann, M.
Casper, J.
Freund, M.
Kahl, C.
ONKOLOGIE, 2010, 33 : 164 - 164
[7] Conditioning with Treosulfan and Fludarabine for Patients with Refractory or Relapsed Non-Hodgkin Lymphoma (NHL)
Schmitt, Michael
Trenschel, Rudolf
Sayer, Herbert G.
Schneider, Catarina
Glass, Aenne
Hilgendorf, Inken
Treschl, Anne
Junghanss, Christian
Borchert, Kersten
Koenigsmann, Michael
Casper, Jochen
Beelen, Dietrich
Freund, Mathias
Kahl, Christoph
BLOOD, 2011, 118 (21) : 1753 - 1753
[8] IMMUNODEFICIENCY AND PROGNOSIS IN NON-HODGKIN LYMPHOMA (NHL)
ANDERSON, TC
JONES, SE
MOON, TE
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 252 - 252
[9] PSEUDOTUMOR AND NON-HODGKIN LYMPHOMA (NHL) OF THE CONJUNCTIVA
KHALIL, HA
DEKEIZER, RJW
INTERNATIONAL OPHTHALMOLOGY, 1987, 11 (02) : 118 - 118
[10] MicroRNAs and pediatric non-Hodgkin lymphoma (NHL)
Miles, R. R.
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 5 - 5

← 1 2 3 4 5 →